DNB initiates monitoring of Isofol

DNB initiates monitoring of Isofol
July 4, 2018 Admin Isofol

July 4, 2018

DNB initiates monitoring of Isofol

The Norwegian Bank (DNB) has initiate the monitoring of Isofol Medical AB.

 

DNB

 

For more information, please contact:
Anders Rabbe, CEO, Isofol Medical AB
E­-mail: anders.rabbe@isofolmedical.com
Phone: +46 (0) 31 797 22 80

About arfolitixorin
Arfolitixorin is a new drug developed to increase the efficacy of the cytotoxic agent 5-fluorouracil (5-FU) and as a rescue drug after high-dose methotrexate treatment. The active ingredient in arfolitixorin, [6R]-5,10-methylenetetrahydrofolate, is the key active metabolite of the widely used folate-based drugs leucovorin and levoleucovorin. Arfolitixorin is suitable for all patients irrespective of their capacity to activate folates since it does not require metabolic activation to exert its effect.

About Isofol Medical AB (publ)
Isofol Medical AB (publ) is a drug development company within the field of oncology developing arfolitixorin, primarily as a treatment for advanced colorectal cancer and as a rescue drug after high-dose methotrexate treatment in osteosarcoma (bone cancer). Through a worldwide exclusive license agreement, Isofol holds the rights to develop and commercialise arfolitixorin within oncology with access to the unique patented production process and the production capabilities of Merck KGaA, Darmstadt, Germany. Isofol Medical AB is traded on the Nasdaq First North Premier. Certified Adviser is FNCA Sweden AB.

www.isofol.se